Unique ID issued by UMIN | UMIN000028730 |
---|---|
Receipt number | R000032799 |
Scientific Title | Effect of PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitor on long term outcomes in patients with acute myocardial infarction: multicenter randomized controlled trial |
Date of disclosure of the study information | 2017/09/04 |
Last modified on | 2023/08/14 12:24:50 |
Effect of PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitor on long term outcomes in patients with acute myocardial infarction: multicenter randomized controlled trial
Effect of PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitor on long term outcomes in patients with acute myocardial infarction: multicenter randomized controlled trial
Effect of PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitor on long term outcomes in patients with acute myocardial infarction: multicenter randomized controlled trial
Effect of PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitor on long term outcomes in patients with acute myocardial infarction: multicenter randomized controlled trial
Japan |
Acute myocardial infarction
Cardiology |
Others
NO
We examine the secondary preventive effect of acute phase use of PCSK9 inhibitors after coronary intervention in patients with acute myocardial infarction.
Efficacy
Progression of coronary lesion after 8 months (QCA, with or without rapid progression)
Cardiovascular death, non-fatal myocardial infarction, stroke, and intervention for de novo coronary lesions
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Active
2
Treatment
Medicine |
As a control group, receive standard treatment, including 2 mg of pitavastatin.
As a PCSK 9 inhibitor group, in addition to standard treatment, including 2 mg of pitavastatin, a PCSK9 inhibitor (Ebolocumab 140 mg) is administered immediately after admission and before discharge.
20 | years-old | <= |
90 | years-old | >= |
Male and Female
Acute myocardial infarction patients who succeeded in coronary intervention treatment within 24 hours after onset of symptoms
cardiogenic shock, dialysis cases, cardiopulmonary arrest, severe liver disease, active malignancy, Unable to ingest statins, patients using PCSK9 inhibitors, patients with side effects on PCSK9 inhibitors in the past , Participating in another trial, a patient who is pregnant or has a possibility of pregnancy, a patient judged inappropriate by another doctor
180
1st name | |
Middle name | |
Last name | Masayuki Doi |
Kagawa Prefectural Central Hospital
Cardiology
1-2-1 Asahi-machi, Takamatsu, Kagawa, Japan
087-811-3333
mdoimd@gmail.com
1st name | |
Middle name | |
Last name | Masayuki Doi |
Kagawa Prefectural Central Hospital
Cardiology
1-2-1 Asahi-machi, Takamatsu, Kagawa, Japan
087-811-3333
mdoimd@gmail.com
Kagawa Prefectural Central Hospital
None
Self funding
NO
2017 | Year | 09 | Month | 04 | Day |
Unpublished
Terminated
2017 | Year | 06 | Month | 20 | Day |
2017 | Year | 09 | Month | 04 | Day |
2017 | Year | 09 | Month | 04 | Day |
2020 | Year | 06 | Month | 19 | Day |
2017 | Year | 08 | Month | 18 | Day |
2023 | Year | 08 | Month | 14 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000032799
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |